YaoGeJu

YaoGeJuCDE public lists · weekly counts

National Drug-Review Weekly

The available CDE acceptance records list 11 drug applications between 29 September 2023 and 5 October 2023 (data as of 13 November 2026 06:00). Of these, generic applications numbered 2, covering 2 drug names.

2023/09/29 – 2023/10/05

Period
2023/09/29 to 2023/10/05, 7 days inclusive
Data as of
2026/11/13 06:00
Cached records
94,806 acceptance records, 11,656 under review now
Source
Public data from the CDE acceptance list and under-review list
New acceptances this week
11
Drugs with new generic filings (by drug name, de-duplicated)
2
Accepted this week, now under review
0

DefinitionAcceptance numbers accepted this week that still appear on CDE's under-review list at the data cutoff; counted by acceptance date from the daily full pull of that list, independent of snapshot history.

Names with a public page are linked.

New acceptances this week

By application type and drug type

11filings, 2 of them generic

By application type

Application typeFilings
Supplement6
Generic2
New drug2
Import1

By drug type

Drug typeFilings
Chemical drug6
TCM4
Therapeutic biologic1

DefinitionAcceptance numbers whose acceptance date falls in this week; application type and drug type are the CDE list's own text, with empty values shown as “Unspecified”.

Most new generic filings, by drug

2 drugs with new generic filings; top 10 listed

#DrugNew generic filingsFiling companiesUnder review, all years
1Carboplatin Injection1110
2Venlafaxine Hydrochloride Sustained-Release Capsules110

DefinitionThis week's acceptance numbers with application type “Generic”, grouped by identical drug name; filing companies are de-duplicated by first applicant; under review, all years = acceptance numbers for that name, from any year, still on the CDE under-review list. Top 10 by filings, then companies.

Most new acceptances, by company

9 companies with new acceptances; top 10 listed

#Company (first applicant)FilingsDrugsGeneric
1Jiangxi Jiu Hua Pharma Co., Ltd. romanized320
2Puma Biotechnology Inc.110
3Takeda Pharmaceuticals U.S.A. Inc.110
4Hua Run San Jiu (Nanchang) Pharma Co., Ltd. romanized110
5Hua Run Shuang He Pharma Co., Ltd. romanized110
6Sichuan Bai Li Pharma Co., Ltd. romanized111
7Tianjin Mei Hua Biopharmaceuticals Technology Co., Ltd. romanized111
8Hainan Ri Zhong Tian Pharmaceutical Co., Ltd. romanized110
9Suzhou Luo Cheng Biopharmaceuticals Co., Ltd. romanized110

DefinitionThis week's acceptance numbers grouped by first applicant; drugs are de-duplicated by drug name; “Generic” counts filings with application type “Generic”. Top 10 by filings.

Under-review list changes

Compared across this platform's snapshots of the under-review list

Data collected since 2026/10/22. There is not enough snapshot history for this week yet; counts of filings entering and leaving review start with the next complete week.

DefinitionEntered review = acceptance numbers seen for the first time in this platform's under-review snapshots this week, excluding the baseline records of the first snapshot day (2026/10/22). Left review = acceptance numbers whose last snapshot sighting falls in this week and that this snapshot no longer lists; the outcome follows NMPA's approval-document delivery notices, and numbers without such a record are marked to be checked. Companies are counted by first applicant.

Class 3 and new-drug acceptances

3 this week

AcceptedDrugApplicants
2023/09/29Import · Class 2.4 马立巴韦片 · No verified English nameJXHL2300245 Takeda Pharmaceuticals U.S.A. Inc.; Takeda(China) International
2023/09/29New drug · Class 1 NB002注射液 · No verified English nameCXSL2300663 Suzhou Luo Cheng Biopharmaceuticals Co., Ltd. romanized
2023/09/29New drug · Class 2.2 巯嘌呤微片 · No verified English nameCXHS2300091 Hua Run Shuang He Pharma Co., Ltd. romanized

DefinitionThis week's acceptance numbers with application type “New drug”, or registration applications whose class starts with 1, 2 or 3 (supplements and re-registrations excluded); newest first, at most 30 rows.

Subscribe to the weekly

No account needed.

The email carries the same content as this page, in the language you subscribe in: section counts, top-10 lists and definitions, with a link to the full report. Your address is used only to send the report.

A text version of this report, weekly, in the language you subscribe in. You will receive one confirmation email first; sending starts only after you click its link. Every issue carries an unsubscribe link.